Boehringer pulls plug on dabigatran’s heart valve trial

| | Cardiovascular Business | Structural Heart Disease

Boehringer Ingelheim has voluntarily discontinued treatment with dabigatran (Pradaxa) in a Phase 2 clinical trial in patients with artificial heart valves. The company based its decision on interim results from the phase 2 RE-ALIGN trial, which suggested that the investigated dosing regimen did not achieve the desired results in this patient population.

Dabigatran is not approved and not recommended for use in patients with prosthetic heart valves. The presence of an artificial heart valve in patients is a clinical condition that is distinct from those for which dabigatran is an approved treatment. In view of the interim trial results, the company said it is currently in discussions with regulatory authorities to reinforce the product label text accordingly and to discuss appropriate communication to physicians and relevant healthcare providers.

In the U.S., dabigatran is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 

 

Related Content

Treating younger patients with TAVR increases risk of death
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
New data put a spotlight on troubling TAVR trends
How robotic-assisted mitral valve repair compares to conventional surgery
Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data
Cardiology societies push Medicare to pay for tricuspid TEER

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup